Chronic Methylmercury Exposure Induces Production of Prostaglandins: Evidence From A Population Study and A Rat Dosing Experiment

Hang-kin Kong[†], Chun-fang Gan[‡], Min Xiong[‡], Kevin Wing-hin Kwok[†], Gilbert Chiu-sing Lui[└], Ping Li[§,¶]*, Hing-man Chan[†,∥] and Samuel Chun-lap Lo[†]*

[†] *Food Safety and Technology Research Center, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong*

[‡] *School of Public Health & Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University, Guiyang 550025, China*

[└] *Department of Statistics and Actuarial Science, The University of Hong Kong, Pokfulam, Hong Kong*

[§] *State Key Laboratory of Environmental Geochemistry, Institute of Geochemistry, Chinese Academy of Sciences, Guiyang 550081, China*

[¶] *CAS Center for Excellence in Quaternary Science and Global Change, Xi'an, 710061, China.*

[∥] *Department of Biology, University of Ottawa, Ottawa, ON K1N 6N5, Canada*

***Co-Corresponding Authors:**

Prof. Samuel Chun-Lap Lo, Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong SAR, China.

Phone: (852)-3400-8669

E-mail: Samuel.chun-lap.lo@polyu.edu.hk

Prof. Ping Li, State Key Laboratory of Environmental Geochemistry, Institute of Geochemistry, Chinese Academy of Sciences, Guiyang, China.

Phone: (86) 851-84391375

E-mail: liping@mail.gyig.ac.cn

TOC



Abstract

Methylmercury (MeHg) is a well-known environmental neurotoxicant affecting millions worldwide who consume contaminated fishes and other food commodities. Exposure to MeHg has been shown to associate positively with some chronic diseases including cardiovascular diseases, but the mechanism is poorly characterized. MeHg had been shown to affect prostaglandin (PG) regulations in *in vitro* studies, but neither *in vivo* nor human studies investigating the effects of MeHg on PG regulations has been reported. Thus, the current study aimed to investigate the association between MeHg exposure and serum PG concentrations in a cross-sectional study among human adults followed by a validation investigation on the cause-effect relationship using a rat model. Firstly, a total of 121 women were recruited from two cities; Wanshan and Leishan in Guizhou, China. Statistical analysis of the human data showed a positive association between blood total mercury (THg) levels and serum concentrations of PGF2α, 15-deoxy-PGJ2, and PGE2 after adjusting for the site effect. In the animal study, adult female Sprague−Dawley rats were dosed with 40 μg MeHg/kg body weight/day for 12 weeks. Serum 15-deoxy-PGJ2 and 2,3d-6-keto-PGF1α concentrations were found to increase significantly after 6-weeks and 10-weeks of MeHg dosing respectively while serum PGF2α concentration increased significantly after 12-weeks MeHg

58 dosing. Combined results of our human and rat studies have shown that chronic
59 MeHg exposure induced dysregulation of PG metabolism. As PGs are a set of
60 mediators with very diverse functions, its abnormal production may serve as the
61 missing mechanistic link between chronic MeHg exposure and various kinds of
62 associated clinical conditions including neurodegeneration and cardiovascular
63 diseases.
64
65 Keywords: Methylmercury, Prostaglandin, Chronic exposure, Metabolomics,
66 Wanshan

INTRODUCTION

Methylmercury (MeHg) is a well-known environmental pollutant bioaccumulated and biomagnified to higher levels in marine fishes at high trophic levels.[1] The problem of chronic exposure to MeHg through diet has been around for decades. Recommended by the Food and Agriculture Organization of the United Nations (FAO), the provisional tolerable weekly intake (PTWI) of MeHg is 1.6 μg/ kg body mass/ week. Estimates of per capita mercury intake through fish consumption in a ten years survey (2001-2011) showed that 38% of the population in 175 countries had exposure higher than the PTWI.[2] In addition, consumption of MeHg contaminated rice is another major route of exposure as it was revealed that rice paddies were active sites for methylation of inorganic Hg to produce MeHg.[3] Consumption of these rice and other food produce grown near Hg mining and related industrial sites would lead to increased MeHg exposure.[4] As millions are exposed to MeHg continuously and its health implications are large, there is a need to document and understand the potential health impacts of chronic MeHg exposure.

Several cohort studies on populations with frequent fish consumption in the Faroe Islands, Spain and Hong Kong were performed to investigate possible associations among abnormal physiological, behavioural outcomes and chronic exposure to MeHg. It was shown that prenatal MeHg exposure affects cognitive

functions developments in children.[5-7] However, despite these studies, potential health impacts of chronic exposure to low dose MeHg on adults are still unclear.[8] Cohort studies conducted in Minamata of Japan suggested that there is a casual relationship between chronic MeHg exposure and development of psychiatric symptoms among adults.[9] Others proposed that MeHg played a role in the pathogenesis of neurodegenerative diseases, as well as increasing resting heart rate and blood pressure.[10, 11] Another meta-analysis showed a significant dose-response between MeHg exposure and blood pressure.[12] There is evidence suggesting the association between chronic MeHg exposure and risk of developing neurodegenerative as well as cardiovascular abnormalities. However, the mechanism is poorly characterized.

Prostaglandins (PG) are lipid autacoids derived from arachidonic acid. They sustain homeostatic functions such as modulation of blood pressure[13] and mediate pathogenic mechanisms, including the inflammatory response[14] and neurodegenerative diseases.[13] From PubMed, nine studies were reported which investigated effects of Hg/ MeHg exposure on PG production. Eight reports were *in vitro* studies, mainly with brain and vascular endothelial cell cultures. It was reported that inorganic HgCl exposure increased production of arachidonic acid (AA), total PGs, thromboxane B2 (TXB2), and 8-isoprostane via activation of lipid

105 signaling enzyme phospholipase A2 in bovine pulmonary artery vascular endothelial
106 cells.[15] Yoshida et al. added that prostacyclin (PGI2) and prostaglandin E2 (PGE2)
107 were released from human brain microvascular endothelial cells upon MeHg
108 exposure.[16] Apart from *in vitro* studies, there was only one *in-vivo* study which used
109 a high concentration of $HgCl_2$ (2.5 mg/kg) to induce kidney failure in rats and was
110 aimed to investigate the effect of agonists to PG receptors for treating chronic and
111 acute kidney failure.[17] Effects of chronic MeHg exposure on PG regulation remain
112 unknown.

113 The objective of this study is to investigate the relationship between long-term
114 MeHg exposure and serum PG concentrations in humans and rats. We hypothesized
115 that chronic MeHg exposure may dysregulate PG metabolism. To test this
116 hypothesis, we conducted a cross-sectional population study on healthy women at
117 child-bearing age who lived in two cities; Wanshan and Leishan in Guizhou
118 province, China. Wanshan was a historic mercury mining area in the eastern part of
119 Guizhou Province. It was one of the largest Hg mining areas in China and had a long
120 history of mining activities dated back to the Qin Dynasty (~221 B.C.). The mining
121 activities have resulted in severe inorganic Hg and MeHg contamination to the local
122 freshwater system, freshwater fish and soil.[18, 19] All mining activities were banned
123 since 2001. However, residents in Wanshan are still exposed to Hg through

consumption of local cultivated rice, vegetables as well as poultry.[4] On the other hand, Leishan has no history of Hg mining and locates in the same province, it was selected as a control site. In order to confirm the cause-effect relationship without complication induced by other confounding factors, a rat dosing study under controlled environment was also conducted.

MATERIALS AND METHODS

Ethics Approval

All procedures dealing with human and human samples were performed in the Chinese Mainland while all the animal work was performed in Hong Kong. All procedures on human subjects were approved by the Ethics Committee of the Affiliated Hospital of Guizhou Medical University and the Human Subjects Ethics Subcommittee of the Hong Kong Polytechnic University. All procedures on the animals were approved by The Animal Subjects Ethics Subcommittee of the Hong Kong Polytechnic University.

Human Subject Recruitment

Women (N=74) who lived in Wanshan for at least 6 months and gave birth at local hospitals without known clinical condition were recruited. Similarly, women

143 (N=47) who lived in Leishan for at least 6 months and gave birth at local hospitals
144 without known clinical condition were recruited. Demographic and dietary
145 information were collected by a questionnaire. The questionnaire was designed
146 according to guidelines from the WHO European Center for Environment and
147 Health, and modified as described in our previous study.[4] Detail descriptions for
148 demographic and dietary survey were provided in the Supporting Information.
149
150 **Collection of Whole Blood and Serum Samples**
151 Approximately 5 ml of whole blood were collected from each participant 2-3
152 days before childbirth using a metal-free plastic vacutainer without anticoagulant for
153 THg analysis. In addition, another 2 ml of whole blood per subject was collected and
154 allowed to clot at room temperature for 30 minutes. The clot was removed by
155 centrifugation at 2000 xg at 4℃ for 10 minutes. Serum was harvested, aliquoted and
156 stored at -80℃ for PG analysis. The USEPA method 1631 was adopted to quantify
157 THg in the human whole blood. The detection limit was 0.5 ng/ L and THg was
158 detected in all samples in this study. Details of the methodology used were provided
159 in the Supporting Information.
160
161 **Quantification of Prostaglandins in Human Serum by ELISA**

Serum concentrations of thromboxane A2 (TXA2), prostacyclin (PGI2), prostaglandin E2 (PGE2), prostaglandin F2α (PGF2α), 15-deoxy-δ 12, 14-prostaglandin J2 (15-deoxy-PGJ2) were quantified using ELISA assay kits purchased from Abnova (Germany). As TXA2 and PGI2 have relatively short half-lives, their serum concentrations were estimated by measuring concentrations of their stable derivatives using ELISA. The serum concentration of TXA2 was estimated by quantifying serum concentration of thromboxane B2 (TXB2, a hydrated form of TXA2). The serum concentration of PGI2 was estimated by quantifying total serum concentrations of 6-keto-prostaglandin F1α (6-keto-PGF1α) and 2, 3-dinor-6-keto- prostaglandin F1α (2,3d-6-keto-PGF1α) as they are produced during PGI2 degradation. The assays were performed according to procedures recommended by the manufacturer with modifications. Details of the procedures were provided in the Supporting Information.

Animal Treatments and Serum Samples Preparations

The rat model used in this study was adopted from our previous one.[20] Sprague−Dawley (SD) rats (all female, 200 to 220 g, 6 to 8 weeks old) were housed in a controlled environment (20 ± 1 °C, 12 hours light/ 12 hours dark cycle). Food and water were provided *ad libitum*. Rats were randomly divided into the sham,

corn-oil vehicle, and MeHg groups. Each group had 12 animals. Rats in the MeHg group were fed by oral gavage with 40 μg of MeHg in corn oil/ kg body weight per day. Rats fed with this dose were aimed to mimic chronic exposure to a sub-toxic dose of MeHg without showing any apparent observable toxic effects. Rats in the vehicle group were fed by oral gavage with 0.1 ml of corn oil. Rats in the sham group received the feeding procedures with neither MeHg nor corn oil administration. Bi-weekly body weight measurements were taken to gauge the health of these rats. For every two weeks until the end of the 12 weeks of MeHg administration, blood samples were collected from each rat. After collecting the blood samples, the blood samples were allowed to clot at room temperature for 30 minutes before being centrifuged at 2000 x g for 10 minutes at 4 ℃. Serum samples were collected and apportioned into 0.2 ml aliquots and stored at -80 ℃ before analysis. After 12 weeks of experiment, all rats were sacrificed. THg concentrations in the rat serum samples were quantified using direct thermal decomposition coupled with atomic absorption spectrometry (MA-3000 from NIC, Japan). Details of the methodology were provided in the Supporting Information.

Sample Preparation for Untargeted Metabolomic Analysis on Rat Sera

The preparative protocol was adopted from a previous study with

modifications.[21] Each 200 µl serum sample was mixed with 600 µl of ice-cold methanol before being shaken vigorously. The mixtures were allowed to stand for 15 minutes before being centrifuged at 13000 g at 4 ℃ for 10 minutes. Supernatants were recovered and filtered with 0.22 µm membrane. The filtrates were concentrated with a vacuum concentrator (Labconco, USA). Subsequently, the concentrates were reconstituted with 20 % methanol in 0.1% formic acid (FA). Tridecanoic acid (0.5 ppm, Sigma-Aldrich, USA) was added as an internal standard. Samples for quality control (QC samples) were prepared by mixing all serum samples from the rats within the same group in equal portion. Subsequently, there were 3 QC samples in total, one from each group.

Untargeted Metabolomic Analysis

Rat serum metabolites profiles were acquired using ultra high-performance liquid chromatography (UHPLC) coupled with dual Agilent jet stream electrospray ionization quadrupole time-of-flight mass spectrometer (Dual-AJS-ESI Q-TOF MS) (Agilent, USA). When loading into the system, 10 µl sample was injected regularly. Reverse phase C_{18} column (Eclipse plus C_{18} column, 150 mm x 2.1 mm i.d., 1.8 µm particle sizes) was used to separate the serum metabolites. The column was equilibrated with 0.1 % FA and eluted with a linear gradient of methanol, starting

from 5 % to 80 % in 30 minutes. The flow rate was 0.2 ml/ minute. Mass calibrant mix (Agilent, USA) was simultaneously injected with the eluate into the Q-TOF MS to perform real-time mass calibration. The metabolites were analyzed with both full-scan positive ion and negative ion modes separately. Detail conditions of the Q-TOF MS were provided in the Supporting Information. The serum samples and QC samples were run in randomized order to avoid uncertainties from an artifact-related injection order and gradual changes in the MS sensitivity along the whole analysis. Each QC sample was run in triplicates for both positive ion and negative ion MS scanning. The raw data was then analyzed using MassHunter Quantitative Analysis v. B.04.00 (Agilent, USA), subsequently with online KEGG mapper (http://www.genome.jp/kegg/tool/map_ pathway2.html). Details of strategy and parameters for data analysis were provided in the Supporting Information.

PG Quantifications by Multiple Reactions Monitoring

The prostaglandin standards used in the multiple reactions monitoring (MRM) measurements were purchased from Cayman Chemical, USA. The extraction method of prostaglandins from serum samples for MRM was adopted from a previous study with modifications.[22] Briefly, one volume of serum sample was extracted with 2.5 folds volume of ethyl acetate containing 0.1% FA. The mixture

was sharked vigorously for 30 seconds before centrifuged at 1000g at 4℃ for a minute. The upper layer was collected and dried with a vacuum concentrator (Labconco, USA). The dried extract was dissolved in 50 µl of methanol with 0.1% FA before MRM analysis. The MRM analysis was performed using ultra high-performance liquid chromatography (UHPLC) coupled with dual Agilent jet stream electrospray ionization triple quadrupole mass spectrometer (Agilent 6460, USA). Concentrated extract of 10 µl was injected into the system. Reverse phase C_{18} column (Eclipse plus C_{18} column, 150 mm x 2.1 mm i.d., 1.8 µm particle sizes) was used to separate the prostaglandins. The column was equilibrated with 0.1 % FA, and the mobile phase was ACN with 0.1% FA (B). The flow rate was 0.3 ml/ minute. The elution gradient started with 35% of B, kept for 4 minutes. Then, it changed linearly to 60% of B at 8 minutes, subsequently, changed linearly to 65% of B at 16 minutes. After elution, the column was washed with 100% of B for 3 minutes and then equilibrated with 0.1% FA. The capillary voltage and nozzle voltage for negative ion mode was set at 3.5 kV and 400 V respectively. The gas flow was 8 L/ min, and the gas temperature was 300 ℃. The mass transitions of PGF2α, 15-deoxy-PGJ2 and 2,3d-6-keto-PGF1α were summarized in Table S12 in Supporting information. The peak area of each product ion was calculated using MassHunter Quantitative Analysis v. B.04.00 (Agilent, USA). A t-test was used to

test for the significance of any difference between groups, and the significance was set at $p \leq 0.01$.

Statistical Analysis

Pearson Chi-square test was used to determine the relevance of demographic characteristics and the dietary consumption frequencies of various food items in relations to the study sites, blood THg levels as well as various serum PG concentrations. Shapiro-Wilk test was used to test for normality of the data. Since the data of human blood THg and serum concentrations of PGs were non-normal, Spearman and partial Spearman rank correlations were used to determine the correlation and significance of blood THg levels and serum concentrations of various prostaglandins with and without adjustments respectively. The adjustments made included age, smoking and drinking habits, as well as aquatic food produce and freshwater fish consumption. Partial least squares regression was performed in R using study site, blood THg level, demographic background and dietary consumption frequencies as predictor variables as well as serum PG concentrations as dependent variables. Concentrations of PGF2a and 15-deoxy-PGJ2 were log-transformed to achieve normal distribution before the regression analysis. Lastly, in order to find if there are other previously unknown confounding factor besides

MeHg that may induce prostaglandins dysregulation, Directed Acyclic Graphs (DAG) were constructed using R. This technique was reported to have less bias in adjusting for potential confounding factors.[23] Structure of DAG was determined by a hill climbing approach to determine the structure DAG model by the maximization of BIC (Bayesian Information Criterion) score and the detail of this approach has been described previously.[24] After the model structure has been decided, the parameters of DAG model are obtained by the maximum likelihood estimation and this approach is suitable for dataset with both discrete and continuous variables in this study. Relationships of variables in the DAG models were presented numerically with their conditional probability. Two-way ANOVA was used to test for the significances of increase in body weight and serum THg levels among rats in different groups. A *t*-test was used to determine the significances of relative abundances of serum metabolites among rats in vehicle group and MeHg group in the metabolomics analysis. One-way ANOVA was used to determine the significances of serum concentrations of various prostaglandins in rats from different groups quantified by ELISA. Student's *t*-test was used to determine the significances of serum concentrations of various prostaglandins in rats from the vehicle and MeHg group in MRM analysis. In general, *p*-values less than 0.01 were taken as statistically significant.

RESULTS AND DISCUSSION

Serum PGs and Human Blood THg Levels

Women from Wanshan have significantly higher blood THg levels (mean= 5.47 μg/L) than women from Leishan (mean=1.47 μg/L) (Table 1). Moreover, serum concentrations of PGF2α, PGE2 and 15-deoxy-PGJ2 of women in Wanshan were also higher (Table 1). Serum concentration of prostacyclin (PGI2) was estimated by quantifying concentrations of its stable metabolic derivatives. However, there was no significant difference between 6-keto-PGF1α and 2,3d-6-keto-PGF1α in the sera of the two groups of women (Table 1). The demographic background and dietary consumption frequencies of the subjects in relation to study sites, blood THg levels and dietary consumption frequencies have been summarized in Table S1 to S6 of the Supporting information. Women in Wanshan ate significantly more locally produced rice, local freshwater fishes and poultry, while women in Leishan consumed significantly more aquatic food products and imported freshwater fishes (Table S1). As women in Leishan had significantly lower blood THg levels as well as lower serum concentrations of PGE2, PGF2α and 15-deoxy-PGJ2, thus the subjects in 1st quartiles of blood THg level and serum concentrations of those 3 PGs shared a similar dietary habit with women from Leishan (Table S2 to S6). None of the

demographic backgrounds and dietary consumption frequencies was associated with serum PGI2 concentration.

There were significant and strong correlations (R> 0.5) between blood THg levels and serum concentrations of PGE2, PGF2α and 15-deoxy-PGJ2, but not with PGI2 (Figure 1). The correlations between blood THg levels and serum concentrations of PGs were again found to be strong after adjustments for age, smoking, drinking as well as consumptions of aquatic food product and freshwater fish (Table S7). To further investigate causal relationships between blood THg level, demographic background, dietary consumption frequencies and serum PG concentrations, Partial Least Squares regression (PLS) was also calculated. Over 50% of the variances (PGE2, Log[PGF2α] and Log[15deoxy-PGJ2]) can be explained by the first 3 components (Table S8). In general, blood THg levels (>0.8 in 1^{st} component) and Study sites (>0.5 in 2^{nd} component) were predictor variables with the highest loadings in 1^{st} and 2^{nd} components (Table S9 to S11), explaining around 35 to 55% of the variances. Consumptions on aquatic food produces, imported freshwater fish, poultry and other meats were found to be important predictor variables among 2^{nd} to 6^{th} components (Table S9 to S11), explaining additional 15 to 20 % of the variances. Thus, by PLS regression, blood THg level and Study site were the main causes on increases of serum PGE2, PGF2α and

15-deoxy-PGJ2 concentrations among women in Wanshan and Leishan, followed by dietary habits.

Lastly, individual DAG graphs had been conducted to understand how potential confounding factors relate to blood THg and prostaglandins (Figure S1 to S3). The numerical equations of describing the relationship and the conditional probabilities were provided in the Supporting information. Results showed that site alone could influence PGE2, PGF2α and 15-deoxy-PGJ2, and site also influenced blood THg levels. This confirms our PLS results where site explained some of variation in the dataset. In addition, site also has influence over a number of variables related to diet. One confounding factor was identified through DAG. For PGF2α, drinking was also found to have influence in addition to site. The drinking habitats of mothers in Leishan in our study may therefore also contribute to the change of serum PGF2α concentration. Taken overall, the results of the population study suggest associations between blood THg level and serum PG concentration. It is important to investigate the dose-response relationship using an experimental animal study conducted in controlled environment and serving with constant diets.

Dysregulations of PG Metabolism in MeHg Dosed Rats

A controlled rat study was conducted to validate cause-effect relationship

between chronic MeHg expsoure and the alterations in PG metabolism. Serum THg levels of the MeHg dosed rats reached an average of 65 μg/L of serum at the end of the 12 MeHg-dosing weeks. There was no significant loss in body weight when compared to rats in sham and vehicle group (Figure S4). A non-targeted serum metabolomic study was conducted to investigate metabolic changes induced by the MeHg dosing in the rats using liquid chromatography coupled with a mass spectrometer (LC-MS). Data of both positive ion and negative ion MS scanning were analyzed by principal component analysis (PCA). Serum samples from the vehicle control and MeHg groups (n= 10 in each group) were found to cluster together in the PCA score plot of positive ion MS scanning (Figure S5a). This indicated that most of the positively charged metabolites in the rat serum are nearly the same in both the MeHg dosing and vehicle control groups. There was one metabolite, saccharopine, that was found to be significantly decreased in the serum of rat after dosing with MeHg (Table 2). Data of serum samples from the MeHg group were clearly differentiated from those from the vehicle group in the PCA score plot of negative ion MS scanning (Figure S5b). This indicated that there were some differential expression of some negatively charged serum metabolites upon MeHg dosing. We found that most of the negatively charged metabolites with a significant increase in amounts were clustered into arachidonic acid metabolism,

371 including arachidonic acid (AA), 15-deoxy-PGJ2,
372 11,12-Dihydroxy-5Z,8Z,14Z-eicosatrienoic acid (11,12-DHET), leukotriene B4
373 (LTB4) and leukotriene A4 (LTA4) (Table 2). Only prostaglandin J2 (PGJ2)
374 decreased significantly in the rat serum samples after dosing with MeHg. This
375 suggested that the AA metabolism in the rat was altered by bio-accumulation of
376 MeHg. Most importantly, AA metabolism is the main pathway responsible for the
377 synthesis of various types of PGs. Further, amounts of serum cholic acid,
378 chenodeoxycholic acid and homovanilic acid were found to be significantly
379 increased in MeHg dosed rats (Table 2). Through pathway analysis of possible
380 serum metabolites that were altered by bioaccumulation of MeHg, it is interesting to
381 note that PGs were involved in signal transduction in serotonergic postsynaptic
382 neurons (Figure S6). In fact, inorganic mercuric compounds like HgS were known to
383 reduce levels of serotonin 5-HT in brains of mice.[25]

384 Results of the non-targeted metabolomics study in rats strongly indicated that
385 PGs synthesis of the AA metabolism was altered by chronic exposure to low dose
386 MeHg. However, the mass spectrometric method adopted by the current
387 metabolomic study was not optimized to detect and quantify all kinds of
388 leukotrienes, prostaglandins, and related metabolites in the rat sera samples.
389 Therefore, ELISA and MRM were performed with the rat sera to quantify amounts

390 of these important metabolites. It was found that serum concentrations of
391 15-deoxy-PGJ2, PGF2α, and PGI2 in the rat were significantly increased after
392 MeHg dosing (Figure S7a to S7c), while serum concentrations of TXB2 (a hydrated
393 form of TXA2) and PGE2 showed no significant change (Figure S7d and S7e).
394 Results from the ELISA assays were consistent with those of serum metabolomic
395 analysis, supporting that prostaglandin and leukotriene metabolism was altered by
396 chronic MeHg exposure. Furthermore, dose-response relationships among levels of
397 MeHg, 15-deoxy-PGJ2, 2,3d-6-keto-PGF1α (a stable metabolic derivative of PGI2),
398 and PGF2α were investigated using MRM. Results from MRM revealed that the
399 serum concentrations of 15-deoxy-PGJ2 and 2,3d-6-keto-PGF1α started to increase
400 significantly after 6-week and 10-week MeHg dosing respectively (Figure 2a and
401 2b). On the other hand, serum concentration of PGF2α was found to be elevated
402 significantly at the end of the 12-week MeHg dosing (Figure 2c). These observations
403 suggested that the metabolism in producing 15-deoxy-PGJ2 was altered at a lower
404 level of Hg accumulation, followed by alterations of 2,3d-6-keto-PGF1α and PGF2α
405 metabolisms when THg levels increased further.
406
407 **Potential Clinical Conditions Associated with PG Dysregulations**
408 This is the first human population study showing a positive association between

409 blood THg and serum PG levels. We have also conducted a rat dosing experiment
410 followed by metabolomics study showing that chronic low dose exposure to MeHg
411 can cause a disruption of AA metabolism resulting in an increase of different PGs.
412 PGF2α and 15-deoxy-PGJ2 were found to increase with blood THg in a
413 dose-dependent manner in both human and rat (Figure 3). On the other hand, PGE2
414 was only found to be positively associated with blood THg in human, while the
415 increase of PGI2 levels by MeHg dosing was only found in rats. One of possible
416 explanations for the variation observed was due to intrinsic species difference
417 between human and the rats.[26] Others might suggest that the human subjects were
418 pregnant women and the serum samples were taken some time before labor. It is
419 known that PGI2 was actively produced by endothelial cells of placental vessels.[27]
420 At the time of labor, concentrations of PGE2, PGF2α and 2,3d-6-keto-PGF1α (a
421 PGI2 stable metabolic derivative) in amniotic fluid would increase significantly.[28, 29]
422 In addition, the concentration of PGF2α in maternal blood increases during labor,
423 while the maternal plasma PGE2 level remains nearly constant during pregnancy
424 and parturition.[30] As the PG metabolism changed during pregnancy, so pregnancy
425 may account for the variations in MeHg induced PG dysregulations seen between
426 human subjects and experimental animals. Nonetheless, it should be stressed that
427 increased of PGE2, PGF2α and 2,3d-6-keto-PGF1α were not seen before labor. Our

428 human serum samples were collected 2-3 days before labor. Besides that, the rats
429 were kept in controlled environment and with constant dietary intake, while the
430 human subjects in Wanshan and Leishan were exposed to various living
431 environment and obviously with different diets. It is known that PG metabolism was
432 closely associated with diet and lifestyle.[31] This may introduce unknown
433 confounding factors, which may account for the variations on the alterations of PG
434 metabolism between the human subjects and rats.

435 One of the major biological functions of PGs is to regulate inflammation. PGE2
436 is a well-known inflammatory mediator that induces fever and cause pain
437 sensation.[32, 33] 15-deoxy-PGJ2 exerts anti-inflammatory property by activating
438 peroxisome proliferator-activated receptor γ (PPARγ), subsequently reducing
439 neuro-inflammation as well as a neuronal loss.[34-36] Apart from inflammation, each
440 type of PG plays multiple unique roles in regulating different biological systems.
441 PGF2α was able to induce bronchoconstriction and uterine contraction.[37, 38] PGE2
442 could induce vasodilation, bronchodilation, and regulate motility of gastrointestinal
443 tract.[39-41] PGI2 was a functional antagonist of TXA2. PGI2 was able to induce
444 vasodilation and inhibit platelet aggregation, while TXA2 was able to induce
445 vasoconstriction and activate platelet aggregation.[42-45]

446 As elaborated previously, PGs play important regulatory roles in many

biological systems and various clinical conditions, hence, dysregulation or abnormal expression levels of PGs could cause hypertension as well as neurodegeneration.[46, 47] For example, a high level of 15-deoxy-PGJ2 could induce neuronal apoptosis, and an increase in serum 15-deoxy-PGJ2 concentration was observed in stroke patients.[48, 49] The imbalance of PGI2 and TXA2 has an important implication for a diverse range of cardiovascular disease.[50] The increase of serum PGF2α and its isoform 8-iso-PGF2α was associated with myocardial infarction.[51] Increase in serum PGF2α concentration could reduce bile flow and bile acid secretion in the rat model.[52, 53] Thus, increase in serum concentrations in cholic acid and chenodeoxycholic acid in the current part of rat study, was suspected to be the result of an increase in serum PGF2α concentration induced by dosing with MeHg (Table 2).

In the literature, there were only a few epidemiological studies that focused on the human immune system upon chronic MeHg exposure.[54] The results of this cross-sectional study with limited sample size provided evidence for a positive association between chronic MeHg exposure and PG metabolism. A longitudinal cohort study with larger sample size will be needed to investigate the prevalence of clinical abnormalities among residents in Wanshan to confirm the cause-effect relationship that chronic MeHg exposure can induce PG imbalance leading to

various clinical abnormalities. This will facilitate a better understanding of the potential health impacts in the populations with frequent consumption of MeHg contaminated food.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGEMENTS

This work was supported by National Natural Science Foundation of China (U1812403, 41622208), Key Laboratory of Environmental Pollution Monitoring and Disease Control, Ministry of Education, Guizhou Medical University (GMU-2016-HJZ-01) as well as a research grant from the Hong Kong Polytechnic University (A/C: 4-ZZEG). We gratefully acknowledge the support of the University Research Facility in Chemical and Environmental Analysis (UCEA), University Research Facility in Life Sciences (ULS) as well as the Centralized Animal Facilities (CAF) of The Hong Kong Polytechnic University.

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website. The Supporting Information contained supporting text for Materials and

Methods, 7 figures and 12 tables.

REFERENCES

(1) Driscoll, C. T.; Mason, R. P.; Chan, H. M.; Jacob, D. J.; Pirrone, N., Mercury as a global pollutant: sources, pathways, and effects. *Environ Sci Technol* **2013,** 47, (10), 4967-83.

(2) Lavoie, R. A.; Bouffard, A.; Maranger, R.; Amyot, M., Mercury transport and human exposure from global marine fisheries. *Sci Rep* **2018,** 8, (1), 6705.

(3) Rothenberg, S. E.; Windham-Myers, L.; Creswell, J. E., Rice methylmercury exposure and mitigation: a comprehensive review. *Environ Res* **2014,** 133, 407-23.

(4) Li, P.; Du, B.; Chan, H. M.; Feng, X., Human inorganic mercury exposure, renal effects and possible pathways in Wanshan mercury mining area, China. *Environ Res* **2015,** 140, 198-204.

(5) Oulhote, Y.; Debes, F.; Vestergaard, S.; Weihe, P.; Grandjean, P., Aerobic Fitness and Neurocognitive Function Scores in Young Faroese Adults and Potential Modification by Prenatal Methylmercury Exposure. *Environ Health Perspect* **2017,** 125, (4), 677-683.

(6) Jacobson, J. L.; Muckle, G.; Ayotte, P.; Dewailly, E.; Jacobson, S. W., Relation of Prenatal Methylmercury Exposure from Environmental Sources to Childhood IQ. *Environ Health Perspect* **2015,** 123, (8), 827-33.

(7) Lam, H. S.; Kwok, K. M.; Chan, P. H.; So, H. K.; Li, A. M.; Ng, P. C.; Fok, T. F., Long term neurocognitive impact of low dose prenatal methylmercury exposure in Hong Kong. *Environ Int* **2013,** 54, 59-64.

(8) Ha, E.; Basu, N.; Bose-O'Reilly, S.; Dorea, J. G.; McSorley, E.; Sakamoto,

511 M.; Chan, H. M., Current progress on understanding the impact of mercury on
512 human health. *Environ Res* **2016,** 152, 419-433.
513 (9) Yorifuji, T.; Tsuda, T.; Inoue, S.; Takao, S.; Harada, M., Long-term
514 exposure to methylmercury and psychiatric symptoms in residents of Minamata,
515 Japan. *Environ Int* **2011,** 37, (5), 907-13.
516 (10) Weiss, B., Lead, manganese, and methylmercury as risk factors for
517 neurobehavioral impairment in advanced age. *Int J Alzheimers Dis* **2011,** 2011,
518 607543.
519 (11) Valera, B.; Muckle, G.; Poirier, P.; Jacobson, S. W.; Jacobson, J. L.;
520 Dewailly, E., Cardiac autonomic activity and blood pressure among Inuit children
521 exposed to mercury. *Neurotoxicology* **2012,** 33, (5), 1067-74.
522 (12) Hu, X. F.; Singh, K.; Chan, H. M., Mercury Exposure, Blood Pressure, and
523 Hypertension: A Systematic Review and Dose-response Meta-analysis. *Environ*
524 *Health Perspect* **2018,** 126, (7), 076002.
525 (13) Swan, C. E.; Breyer, R. M., Prostaglandin E2 modulation of blood
526 pressure homeostasis: studies in rodent models. *Prostaglandins Other Lipid Mediat*
527 **2011,** 96, (1-4), 10-3.
528 (14) Ricciotti, E.; FitzGerald, G. A., Prostaglandins and inflammation.
529 *Arterioscler Thromb Vasc Biol* **2011,** 31, (5), 986-1000.
530 (15) Mazerik, J. N.; Mikkilineni, H.; Kuppusamy, V. A.; Steinhour, E.; Peltz, A.;
531 Marsh, C. B.; Kuppusamy, P.; Parinandi, N. L., Mercury activates phospholipase a(2)
532 and induces formation of arachidonic Acid metabolites in vascular endothelial cells.
533 *Toxicol Mech Methods* **2007,** 17, (9), 541-57.
534 (16) Yoshida, E.; Kurita, M.; Eto, K.; Kumagai, Y.; Kaji, T., Methylmercury
535 promotes prostacyclin release from cultured human brain microvascular endothelial
536 cells via induction of cyclooxygenase-2 through activation of the EGFR-p38 MAPK

537 pathway by inhibiting protein tyrosine phosphatase 1B activity. *Toxicology* **2017,**
538 392, 40-46.
539 (17) Vukicevic, S.; Simic, P.; Borovecki, F.; Grgurevic, L.; Rogic, D.; Orlic, I.;
540 Grasser, W. A.; Thompson, D. D.; Paralkar, V. M., Role of EP2 and EP4
541 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure.
542 *Kidney Int* **2006,** 70, (6), 1099-106.
543 (18) Yin, R.; Feng, X.; Wang, J.; Bao, Z.; Yu, B.; Chen, J., Mercury isotope
544 variations between bioavailable mercury fractions and total mercury in mercury
545 contaminated soil in Wanshan Mercury Mine, SW China. *Chem. Geol.* **2013,** 336,
546 (16), 80-86.
547 (19) Qiu, G.; Feng, X.; Wang, S.; Fu, X.; Shang, L., Mercury distribution and
548 speciation in water and fish from abandoned Hg mines in Wanshan, Guizhou
549 province, China. *Sci Total Environ* **2009,** 407, (18), 5162-8.
550 (20) Kong, H. K.; Wong, M. H.; Chan, H. M.; Lo, S. C., Chronic exposure of
551 adult rats to low doses of methylmercury induced a state of metabolic deficit in the
552 somatosensory cortex. *J Proteome Res* **2013,** 12, (11), 5233-45.
553 (21) Wang, X.; Mu, X.; Zhang, J.; Huang, Q.; Alamdar, A.; Tian, M.; Liu, L.;
554 Shen, H., Serum metabolomics reveals that arsenic exposure disrupted lipid and
555 amino acid metabolism in rats: a step forward in understanding chronic arsenic
556 toxicity. *Metallomics* **2015,** 7, (3), 544-52.
557 (22) Huang, Y.; Chen, G.; Liu, X.; Shao, Y.; Gao, P.; Xin, C.; Cui, Z.; Zhao, X.;
558 Xu, G., Serum metabolomics study and eicosanoid analysis of childhood atopic
559 dermatitis based on liquid chromatography-mass spectrometry. *J Proteome Res* **2014,**
560 13, (12), 5715-23.
561 (23) Shrier, I.; Platt, R. W., Reducing bias through directed acyclic graphs.
562 *BMC Med Res Methodol* **2008,** 8, 70.

563 (24) K. Korb; Nicholson, A. Bayesian Artificial Intelligence *Periodical*
564 [Online], 2010.
565 (25) Wang, Q.; Yang, X.; Zhang, B.; Wang, K., Cinnabar is different from
566 mercuric chloride in mercury absorption and influence on the brain serotonin level.
567 *Basic Clin Pharmacol Toxicol* **2013,** 112, (6), 412-7.
568 (26) Granstrom, E.; Kindahl, H., Species differences in circulating
569 prostaglandin metabolites. Relevance for the assay of prostaglandin release. *Biochim*
570 *Biophys Acta* **1982,** 713, (3), 555-69.
571 (27) Nelson, D. M.; Walsh, S. W., Thromboxane and prostacyclin production
572 by different compartments of the human placental villus. *J Clin Endocrinol Metab*
573 **1989,** 68, (3), 676-83.
574 (28) Mitchell, M. D.; Keirse, M. J.; Brunt, J. D.; Anderson, A. B.; Turnbull, A.
575 C., Concentrations of the prostacyclin metabolite, 6-keto-prostaglandin F1 alpha, in
576 amniotic fluid during late pregnancy and labour. *Br J Obstet Gynaecol* **1979,** 86, (5),
577 350-3.
578 (29) Robinson, J. S.; Natale, R.; Clover, L.; Mitchell, M. D., Prostaglandin E,
579 thromboxane B2 and 6-oxo-prostaglandin F1 alpha in amniotic fluid and maternal
580 plasma of rhesus monkeys (Macaca mulatta) during the latter third of gestation. *J*
581 *Endocrinol* **1979,** 81, (3), 345-9.
582 (30) Brennecke, S. P.; Castle, B. M.; Demers, L. M.; Turnbull, A. C., Maternal
583 plasma prostaglandin E2 metabolite levels during human pregnancy and parturition.
584 *Br J Obstet Gynaecol* **1985,** 92, (4), 345-9.
585 (31) Cocate, P. G.; Natali, A. J.; Oliveira, A.; Longo, G. Z.; Alfenas Rde, C.;
586 Peluzio Mdo, C.; Santos, E. C.; Buthers, J. M.; Oliveira, L. L.; Hermsdorff, H. H.,
587 Fruit and vegetable intake and related nutrients are associated with oxidative stress
588 markers in middle-aged men. *Nutrition* **2014,** 30, (6), 660-5.

589 (32) Engstrom, L.; Ruud, J.; Eskilsson, A.; Larsson, A.; Mackerlova, L.;
590 Kugelberg, U.; Qian, H.; Vasilache, A. M.; Larsson, P.; Engblom, D.; Sigvardsson,
591 M.; Jonsson, J. I.; Blomqvist, A., Lipopolysaccharide-induced fever depends on
592 prostaglandin E2 production specifically in brain endothelial cells. *Endocrinology*
593 **2012,** 153, (10), 4849-61.
594 (33) Lin, C. R.; Amaya, F.; Barrett, L.; Wang, H.; Takada, J.; Samad, T. A.;
595 Woolf, C. J., Prostaglandin E2 receptor EP4 contributes to inflammatory pain
596 hypersensitivity. *J Pharmacol Exp Ther* **2006,** 319, (3), 1096-103.
597 (34) Zhao, X.; Zhang, Y.; Strong, R.; Grotta, J. C.; Aronowski, J.,
598 15d-Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma,
599 promotes expression of catalase, and reduces inflammation, behavioral dysfunction,
600 and neuronal loss after intracerebral hemorrhage in rats. *J Cereb Blood Flow Metab*
601 **2006,** 26, (6), 811-20.
602 (35) Scher, J. U.; Pillinger, M. H., 15d-PGJ2: the anti-inflammatory
603 prostaglandin? *Clin Immunol* **2005,** 114, (2), 100-9.
604 (36) Powell, W. S., 15-Deoxy-delta12,14-PGJ2: endogenous PPARgamma
605 ligand or minor eicosanoid degradation product? *J Clin Invest* **2003,** 112, (6),
606 828-30.
607 (37) Fujii, K.; Kohrogi, H.; Iwagoe, H.; Hamamoto, J.; Hirata, N.; Yamaguchi,
608 T.; Kawano, O.; Ando, M., Evidence that PGF2 alpha-induced contraction of
609 isolated guinea pig bronchi is mediated in part by release of tachykinins. *J Appl*
610 *Physiol (1985)* **1995,** 79, (5), 1411-8.
611 (38) Grbovic, L.; Jovanovic, A., Indomethacin depresses prostaglandin F2
612 alpha-induced contraction in guinea-pig uterine artery with both intact and denuded
613 endoth. *Prostaglandins* **1997,** 53, (6), 371-9.
614 (39) Foudi, N.; Kotelevets, L.; Louedec, L.; Leseche, G.; Henin, D.; Chastre, E.;

615 Norel, X., Vasorelaxation induced by prostaglandin E2 in human pulmonary vein:
616 role of the EP4 receptor subtype. *Br J Pharmacol* **2008,** 154, (8), 1631-9.
617 (40) Safholm, J.; Manson, M. L.; Bood, J.; Delin, I.; Orre, A. C.; Bergman, P.;
618 Al-Ameri, M.; Dahlen, S. E.; Adner, M., Prostaglandin E2 inhibits mast
619 cell-dependent bronchoconstriction in human small airways through the E
620 prostanoid subtype 2 receptor. *J Allergy Clin Immunol* **2015,** 136, (5), 1232-9 e1.
621 (41) Iizuka, Y.; Kuwahara, A.; Karaki, S., Role of PGE2 in the colonic motility:
622 PGE2 generates and enhances spontaneous contractions of longitudinal smooth
623 muscle in the rat colon. *J Physiol Sci* **2013,** 64, (2), 85-96.
624 (42) Mori, A.; Namekawa, R.; Hasebe, M.; Saito, M.; Sakamoto, K.; Nakahara,
625 T.; Ishii, K., Involvement of prostaglandin I(2) in nitric oxide-induced vasodilation
626 of retinal arterioles in rats. *Eur J Pharmacol* **2015,** 764, 249-55.
627 (43) Carrier, E.; Brochu, I.; de Brum-Fernandes, A. J.; D'Orleans-Juste, P., The
628 inducible nitric-oxide synthase modulates endothelin-1-dependent release of
629 prostacyclin and inhibition of platelet aggregation ex vivo in the mouse. *J*
630 *Pharmacol Exp Ther* **2007,** 323, (3), 972-8.
631 (44) Guo, S. W.; Du, Y.; Liu, X., Endometriosis-Derived Stromal Cells Secrete
632 Thrombin and Thromboxane A2, Inducing Platelet Activation. *Reprod Sci* **2016,** 23,
633 (8), 1044-52.
634 (45) Ding, X.; Murray, P. A., Cellular mechanisms of thromboxane
635 A2-mediated contraction in pulmonary veins. *Am J Physiol Lung Cell Mol Physiol*
636 **2005,** 289, (5), L825-33.
637 (46) Sacerdoti, D.; Pesce, P.; Di Pascoli, M.; Brocco, S.; Cecchetto, L.;
638 Bolognesi, M., Arachidonic acid metabolites and endothelial dysfunction of portal
639 hypertension. *Prostaglandins Other Lipid Mediat* **2015,** 120, 80-90.
640 (47) Yagami, T.; Koma, H.; Yamamoto, Y., Pathophysiological Roles of

Cyclooxygenases and Prostaglandins in the Central Nervous System. *Mol Neurobiol* **2015,** 53, (7), 4754-71.

(48) Blanco, M.; Moro, M. A.; Davalos, A.; Leira, R.; Castellanos, M.; Serena, J.; Vivancos, J.; Rodriguez-Yanez, M.; Lizasoain, I.; Castillo, J., Increased plasma levels of 15-deoxyDelta prostaglandin J2 are associated with good outcome in acute atherothrombotic ischemic stroke. *Stroke* **2005,** 36, (6), 1189-94.

(49) Koh, S. H.; Jung, B.; Song, C. W.; Kim, Y.; Kim, Y. S.; Kim, S. H., 15-Deoxy-delta12,14-prostaglandin J2, a neuroprotectant or a neurotoxicant? *Toxicology* **2005,** 216, (2-3), 232-43.

(50) Kawabe, J.; Ushikubi, F.; Hasebe, N., Prostacyclin in vascular diseases. - Recent insights and future perspectives. *Circ J* **2010,** 74, (5), 836-43.

(51) Berg, K.; Jynge, P.; Bjerve, K.; Skarra, S.; Basu, S.; Wiseth, R., Oxidative stress and inflammatory response during and following coronary interventions for acute myocardial infarction. *Free Radic Res* **2005,** 39, (6), 629-36.

(52) Weidenbach, H.; Scheibner, J.; Stange, E. F.; Adler, G.; Beckh, K., Reduction of bile secretion by prostaglandins in the rat in vivo. *Life Sci* **1996,** 58, (18), 1531-8.

(53) Beckh, K.; Kneip, S.; Arnold, R., Direct regulation of bile secretion by prostaglandins in perfused rat liver. *Hepatology* **1994,** 19, (5), 1208-13.

(54) Karagas, M. R.; Choi, A. L.; Oken, E.; Horvat, M.; Schoeny, R.; Kamai, E.; Cowell, W.; Grandjean, P.; Korrick, S., Evidence on the human health effects of low-level methylmercury exposure. *Environ Health Perspect* **2012,** 120, (6), 799-806.

Table 1. Blood THg and serum concentrations of PGs in apparently healthy women from Wanshan (Hg mining site) and Leishan (control site).

	Wanshan			Leishan			
	n	mean	95% CI *	n	mean	95% CI	*p* value‡
Age	71□	25.37	(24.24, 26.49)	47	23.51	(22.08, 24.94)	0.089
Blood THg, ng/ ml	74	5.47	(4.77, 6.18)	47	1.47	(1.23, 1.72)	< 0.001
Serum PGI2, ng/ ml	74	1.77	(1.28, 2.25)	47	1.17	(1.01, 1.32)	0.285
Serum PGE2, ng/ ml	74	3.70	(3.51, 3.89)	47	0.45	(0.27, 0.64)	< 0.001
Serum PGF2α, ng/ ml	74	13.79	(8.43, 19.15)	47	0.33	(0.24, 0.42)	0.007
Serum 15-deoxy-PGJ2, ng/ ml	74	83.08	(40.49, 125.68)	47	0.74	(0.15, 1.33)	0.003

666 * Confidence intervals at a 95 % confident level

667 ‡T test was used to compare means from both groups, *p* value < 0.01 would be considered as significant.

668 □ There were 3 missing data in the age category of the human subjects in Wanshan.

669

670

671


a
PGE2 (ng/ ml)
Blood THg (ppb)
Wanshan
Leishan
R= 0.572, df= 115, p< 0.001

672


b
Log PGF2a
Blood THg (ppb)
Wanshan
Leishan
R= 0.646, df= 115, p< 0.001

673


c
Wanshan
Leishan
Log 15-deoxy-PGJ2
R= 0.54, df= 115, p< 0.001
Blood THg (ppb)
4
3
2
1
0
-1
-2
0
5
10
15
20

674


d
Wanshan
Leishan
PGI2 (ng/ ml)
R= -0.065, df= 115, p= 0.480
Blood THg (ppb)
10
9
8
7
6
5
4
3
2
1
0
0
5
10
15
20

675

676

677 **Figure 1** Correlations between blood THg and serum concentrations of PGs. The
678 correlations between blood THg and serum PG concentrations were calculated by
679 Spearman correlation. (a) Blood THg showed a significant and strong correlation
680 with serum PGE2 concentration. (b & c) Blood THg showed significant and strong
681 correlations with serum concentrations of PGF2α and 15-deoxy-PGJ2 in log scale
682 respectively. (d) No correlation was found between blood THg and serum PGI2
683 concentration. Partial Spearmen correlations between blood THg and serum
684 concentrations of PGs with various adjustments were reported in Table S2 in
685 Supporting Information.

686

687

Table 2 Serum metabolites with significant change in amounts in the MeHg dosed rats.

m/z		Chemical formula	Fold change*	*p* value#	Identified metabolite	KEGG ID+	HMDB ID§
				Positive ion MS scanning			
				KEGG Pathway: Lysine biosynthesis (map00300) & Lysine degradation (map00310)			
277.133	$[M+H]^+$	$C_{11}H_{20}N_2O_6$	0.49	0.0093	Saccharopine	C00449	HMDB00279
				Negative ion MS scanning			
				KEGG Pathway: Arachidonic acid metabolism (map00590) & Serotonergic synapse (map04726)			
303.243	$[M-H]^-$	$C_{20}H_{32}O_2$	4.21	0.0043	Arachidonic acid	C00219	HMDB01043
315.204	$[M-H]^-$	$C_{20}H_{28}O_3$	3.49	0.0028	15-Deoxy-δ-12,14-prostaglandin J2	C14717	HMDB05079
337.247	$[M-H]^-$	$C_{20}H_{34}O_4$	8.26	0.0070	11,12-Dihydroxy-5Z,8Z,14Z-eicosatrienoic acid	C14774	HMDB02314
335.235	$[M-H]^-$	$C_{20}H_{32}O_4$	7.63	0.0016	Leukotriene B4	C02165	HMDB01085
317.199	$[M-H]^-$	$C_{20}H_{30}O_3$	4.17	0.0082	Leukotriene A4	C00909	HMDB01337
333.215	$[M-H]^-$	$C_{20}H_{30}O_4$	0.46	0.0066	Prostaglandin J2	C05957	HMDB02710
				KEGG Pathway: Primary bile acid biosynthesis (map00120)			
407.281	$[M-H]^-$	$C_{24}H_{40}O_5$	3.12	0.00007	Cholic acid	C00695	HMDB00619
391.302	$[M-H]^-$	$C_{24}H_{40}O_4$	1.74	0.0040	Chenodeoxycholic acid	C02528	HMDB00518
				KEGG Pathway: Dopaminergic synapse (map04728)			
181.172	$[M-H]^-$	$C_9H_{10}O_4$	2.91	0.00006	Homovanillic acid	C05582	HMDB00118

688 *Fold change was calculated by dividing the normalized signal of the metabolite in MeHg group with the normalized signal of the metabolite in the vehicle group. Fold
689 change value greater than one meant the amount of the serum metabolite in the MeHg group was higher than that in the vehicle group. Fold change less than one meant the
690 amount of the serum metabolite in the MeHg group was lower than that in the vehicle group. The signal intensities of all the identified metabolites were normalized with
691 the signal of the internal standard.
692 #*p* values were calculated by using a moderated t-test, *p* value< 0.01 was considered as significant differences.
693 + KEGG ID: Unique C number assigned by KEGG for each metabolite in KEGG database
694 §HMDB ID: Unique identity code assigned by Human metabolome database (HMDB) for each metabolite in HMDB database
695
696
697


a
Vehicle
MeHg
Serum 15-deoxy-PGJ2 level (ng/ ml)
Week
0
10
20
30
40
50
60
70
80
90
0
2
4
6
8
10
12
*
*
*
*

698


b
Vehicle
MeHg
Serum 2,3d-6k-PGF1α level (ng/ ml)
Week
0
10
20
30
40
50
60
70
80
0
2
4
6
8
10
12
*
*

699



700

701 **Figure 2.** Changes of serum prostaglandins of interest along the 12-week MeHg

702 exposure. Biweekly serum samples were collected from the vehicle and MeHg

703 groups to monitor the changes of (**a**) 15-deoxy-PGJ2, (b) 2,3d-6-keto-PGF1α and (c)

704 PGF2α. Serum level of 15-deoxy-PGJ2 concentration started to increase

705 significantly ($p< 0.05$) after the 6th-week of MeHg exposure. Serum levels of

706 2,3d-6keto-PGF1α started to increase significantly ($p< 0.05$) after the 10th-week of

707 MeHg exposure. Serum levels of PGF2 increased significantly ($p< 0.05$) at 12th

708 week in the MeHg treated rats. The data were presented as mean ± SD.

709

710



711
712

713 **Figure 3**. Summary of the current human and animal studies. The above pathway
714 was constructed based on KEGG pathway map of arachidonic acid metabolism
715 (map00590). Arachidonic acid (AA) is the common precursor for PGs. AA is first
716 converted to PGH2, subsequently, converted to PGE2, PGF2α, 15-deoxy-PGJ2 and
717 PGI2 via 4 separated pathways. The patterns of dysregulated PGs have minor
718 difference in between the human and rat studies.

719
720